Discover how the innovative mTECH-Rehab trial is revolutionizing cardiac rehabilitation with mobile technology to enhance patient functional status and cardiovascular health.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Rationale and Design of the mTECH-Rehab Randomized Controlled Trial: Impact of a Mobile Technology Enabled Corrie Cardiac Rehabilitation Program on Functional Status and Cardiovascular Health.
Isakadze et al., J Am Heart Assoc 2024
DOI: 10.1161/JAHA.123.030654
New Intervention: Corrie Hybrid Cardiac Rehabilitation Program
Importance: Traditional in-center cardiac rehabilitation (CR) faces accessibility issues, particularly for underrepresented racial and ethnic groups. The Corrie Hybrid CR program aims to address these barriers by integrating technology and offering a flexible, patient-centered approach.
Study Design: The mTECH-Rehab trial is a randomized controlled trial involving 200 patients from 4 hospitals in Maryland, comparing the Corrie Hybrid CR program plus usual care against usual care alone. The intervention includes:
- A mobile app for patient engagement and behavior change.
- Smart devices for health metrics collection.
- Initial in-center sessions followed by a mix of home and in-center CR.
- A clinician dashboard for health data monitoring.
- Weekly virtual coaching over 12 weeks.
Primary Outcome: The main measure of success is the difference in the 6-minute walk test (functional capacity) at 12 weeks post-randomization between the two groups.
Secondary Outcomes: These include improvements in cardiovascular health, CR engagement, quality of life, health factors (e.g., cholesterol, weight, diet), and psychosocial factors.
Contribution to Literature: This trial could demonstrate an effective alternative to traditional CR, potentially improving outcomes and access to care. The results will be published after completion of data collection and analysis.
Clinical Trial Registration: The study is registered at clinicaltrials.gov with identifier NCT05238103.